Dto Law
General
Cases7
Challenger50%
Patent Owner50%
NPE50%
--
--
Practice Areas
CommunicationsMech Eng, ManufDesign
Top Attorneys
Elite Ratings
DCTPTABCAFC
Analytics
Lawyers
Cases
Ratings Trends
Practice Areas
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 05/13/22 | Request to Appear Pro Hac Vice (Filing fee received: $213.00 receipt number ACASDC-16823343.)(Application to be reviewed by Clerk.)(Prey, Rose)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Request to Appear Pro Hac Vice (Filing fee received: $213.00 receipt number ACASDC-16823343.)(Application to be reviewed by Clerk.)(Prey, Rose)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Summons Issued. Counsel receiving this notice electronically should print this summons and serve it in accordance with Rule 4, Fed.R.Civ.P and LR 4.1. (cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Summons Issued. Counsel receiving this notice electronically should print this summons and serve it in accordance with Rule 4, Fed.R.Civ.P and LR 4.1. (cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | REPORT on the filing or determination of an action regarding patent and/or trademark number(s) *8,071,369*, *8,932,856*, *8,951,797*, *8,940,536*, *9,169,490*, *10,457,917* (cc: USPTO)(cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | REPORT on the filing or determination of an action regarding patent and/or trademark number(s) *8,071,369*, *8,932,856*, *8,951,797*, *8,940,536*, *9,169,490*, *10,457,917* (cc: USPTO)(cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Corporate Disclosure Statement by Whitehead Institute for Biomedical Research. No Corporate Parents/ Interested Parties. (cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Corporate Disclosure Statement by Whitehead Institute for Biomedical Research. No Corporate Parents/ Interested Parties. (cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Corporate Disclosure Statement by Fate Therapeutics, Inc. No Corporate Parents / Interested Parties. (cxt)(jrd) (Entered: 05/13/2022) | |
| 05/13/22 | Corporate Disclosure Statement by Fate Therapeutics, Inc. No Corporate Parents / Interested Parties. (cxt)(jrd) (Entered: 05/13/2022) |